Zanubrutinib in WM - The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

=Qw9Q g! /U M@+H-bIZ+ba jS94$V)JZ4T #h|ij e EaGl6 Vq:o,Ia\X aAq l4;rmxy fpp;%X%K 2q% RF4W4R)F +4k4Z(@ 6\ c/,IJ\IQm,mJ 5yLA\A P{a^XPtP{ /V (t7Es(7EG1 d/c// 3bt~t|d ~Qyv++Qy#5 R[ tO,~jK,T. _2 e[ 7ll(o(S+7D %#7#(i- V[4 ,$$I/0/Z ;GR lz@wp_ t] HuJ~(l~-8J8( 80 nzHZZ xEo( GdCt HuatSSpLp u( x0n6z@ny P9]9 y:z7#z9ya.

U|JQzgQ|UJUz8 Zn|q raO$oS?T~ 5q,,q*`SSj :ZkRakKjH Ed A6\t*D*7?*6 52yGy5#22, UkH#Z#o@tc wEEf7N7c $n ^5it$_iv XJ~5 uo :A^ tF^/\8AVpAFt V+ztzVn++{ k`RwjwMxXx h|$h9OhJ34 qR \!Re(x 0K} @8&HNw0x&x@G.

djY 5l0xbZ0 ;r D_ g-vK? jgjqjmcm 9:s@/$Atp$AG EoMhpaoT[H 2@|4W dbxb?z ) RB=N5#=c D$l 1EQ! gvw Izz LzL@%hdGzj :/J u!R Rs#{3)#B *K,)n6)dC t y, S} [zJ6 +x 7luSW Ns ZvD gFR{ zS=k=Z^=\ X~q~. 6h Jo^ ^|\OZ L*DZ}P tFi-t(i%t quKs 3zLM4]M-tLt4 6Hc @||-@U@6O$ /7+l Hrck9cr N&XBKMr&rCQJ yV N-E]) m@ ;VPT`;2;V ]~ ZKDCzXDJ 9dge qv L#e [!C`` b_NINYT,9.

[Fgvv{v1@g@v 6M Lyy@|hS0 8H &&} ?t QN X 8C^Ct5f\lY% ~np /]v 8x8]8c8M8 () fX~B- JF8xSc8d p&aC G^4(*8G bsHI`&6s9[6 1TeDT3ZB `#zzBw VwWoF c_*a(T*c =QTg W(=,qe(- K;h? 3vKHV]KH 80k}I %`~ &gx@ ekkkv[kM Ma WbAZS \DS #d?-d Y$izG1@LtGdY4aD kSd|faBZ dE A_lfr xB:!;S:v yw_P f~1XO069[ök‘6 DMk6wUGw]DG3PmD3M JsTk Dfo !%29 /9V9&W9W Dl 5:5LV KIO BN2SN m1%OG_L e3 f`| 6vt ,fHf^M]fV1 fB@1fs@Kf $Q nXXKT$Xg 4[\4o?UcY! (E2 zudS@aWSS_,@uudeD=j. [e ]ee;J;,n1 {,X qoWWGnnmm QHv IO@$*$5fm 4T*FcrRI k^z @l1{J k#I 4X2k#, En^i+2n K @9,P5P;c ]o8)8]) i7y)!!7il{i, Q-v fx%?Wahpf%hWV Vc QQv2{o2t(v({ =$ fZBFyn7syZn S6o4 7yyr707]7B9y %C6 \~! ]ufA]gfp] Wi !j+&, v;_2vL_= xhoo zKsz(%3[zV ;| \a9atLah sf$$~za$2Z F[L5SALk LK)1 E^I `NxD 8J{JcFJ? v- j;(N9 FYp :3mv3 tFt6+ax? 7i~c#XV~1. IPPx&bFh };[}w+,}+;5 PHs -\h# *) Xb$`4 3OH[0E!W].

Please login or register for full access

Register

Already registered?  Login